Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LPL | P06858 | 8/20 | 0.49 |
| ▸ | LIPG | Q9Y5X9 | 8/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | SPHK1 | Q9NYA1 | 3/20 | 0.36 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.36 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.34 |
| ▸ | F11 | P03951 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12190256 | 0.96 | LPL (0.52) | LPLLIPGMEN1MAPK1KMT2A | |
| SCHEMBL22820280 | 0.93 | LPL (0.49) | LPLLIPGMEN1MAPK1KMT2A | |
| SCHEMBL17072248 | 0.91 | MEN1 (0.47) | LPLLIPGMEN1MAPK1KMT2A | |
| SCHEMBL12190257 | 0.87 | MEN1 (0.50) | LPLLIPGMEN1MAPK1KMT2A | |
| SCHEMBL18961304 | 0.83 | LPL (0.40) | LPLLIPGMEN1MAPK1KMT2A | |
| SCHEMBL10893963 | 0.83 | CYP2C9 (0.50) | MEN1MAPK1KMT2ACYP2C9MAPT | |
| SCHEMBL10896142 | 0.83 | CYP2C9 (0.50) | MEN1MAPK1KMT2ACYP2C9MAPT | |
| SCHEMBL10893968 | 0.83 | CYP2C9 (0.50) | MEN1MAPK1KMT2ACYP2C9MAPT | |
| SCHEMBL16011399 | 0.82 | CA1 (0.51) | LPLLIPGCYP2C9MAPTALDH1A1 | |
| SCHEMBL1962980 | 0.82 | CYP2C9 (0.42) | LPLLIPGMEN1MAPK1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11760934-B2 | Polymerizable compound, and liquid crystal composition and liquid crystal display element in which the compound is used | DIC CORPORATION (JP) | 2023-09-19 | — | — | US | disclosed |
| US-11760934-B2 | Polymerizable compound, and liquid crystal composition and liquid crystal display element in which the compound is used | DIC CORPORATION (JP) | 2023-09-19 | — | — | US | disclosed |
| US-20200308488-A1 | POLYMERIZABLE COMPOUND, AND LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY ELEMENT IN WHICH THE COMPOUND IS USED | DIC CORPORATION (JP) | 2020-10-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11760934-B2 | Polymerizable compound, and liquid crystal composition and liquid crystal display element in which the compound is used | SFXN1, SFXN3, SIK3 | LPL 4327/4885LIPG 4367/4885MEN1 3058/4885 |
| US-20200308488-A1 | POLYMERIZABLE COMPOUND, AND LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY ELEMENT IN WHICH THE COMPOUND IS USED | SFXN1, SFXN3, SIK3 | LPL 4327/4885LIPG 4367/4885MEN1 3058/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.